THE Therapeutic Goods Administration (TGA) has decided to seek further advice in relations to amending the scheduling of psilocybin and MDMA.
The review will assess the therapeutic value, risks and benefits to public health outcomes for these substances.
A final decision is due on 22 Apr.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Apr 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Apr 21